SPID®-Technology

Laxxon Medical owns the exclusive worldwide rights for the development, production and commercialization of innovative drug delivery systems on the basis of a worldwide patented large-scale 3D screen printing technology (SPID®-Technology).


SPID® (Screen Printed Innovative Drug) Technology is Laxxon’s additive 3D screen-printing and manufacturing process. With our patented technology, we can produce a generation of smart drug delivery systems (DDSs) with tailored pharmacokinetics based on advanced geometric internal structures, heterogenous distribution of active ingredients and choice of materials. 

 

What is 3D Screen Printing?

3D Screen Printing is a proprietary additive manufacturing technology. It enables custom geometry, size, inner architecture allowing discontinuous distribution of active pharmaceutical ingredient(s) (API) within in given dosage form, and therefore offers high flexibility with regard to dosing and tailoring of drug release profiles.

Our 3D screen printing uses a screen mesh to transfer a semi-solid, API-containing paste onto a plate, except in areas made impermeable to the paste. The deposited layer is then dried. The next layer is printed precisely on top of the previous one after lifting the screen by the dried layer thickness.


Screen printing has the potential for mass customization enabling the build-up of thousands of units per screen simultaneously. The number of units printed simultaneously is largely defined by the ratio of screen size to unit size. This differentiates screen printing from other 3DP technologies, whose capacity is limited by the number of printing heads.

3D screen printing, a fully automated technology, adds the third dimension to the classical form of screen printing. It offers high freedom in choice of materials. Material is only added where structures are being built-up. Thickness of walls (X-Y dimensions) spans from 50µm to several centimeters. Bank heights range from 10µm to several centimeters. Single layers vary in thickness from 10µm to 100µm (screen) and beyond (pattern).

 
 

Manufacturing & Patient Benefits

High Precision Drug Delivery Opportunities

  • High-precision release profiles for oral tablets and pills – fast onset of action up to long-lasting retarding effects

  •  Mucoadhesive, peroral and transdermal dosage forms

  • Multiple API combinations in one DDS

  • Reduction of multiple daily dosages to one

  • Innovation of improved drug delivery for established APIs generates opportunities for new patents on improved DDS

  • Company operates its application lab and ordered its first 3D production unit capable of mass production under GMP (Good Manufacturing Practice) 

Mass Production & Small Batch

  • Enables mass-production (up to 1.5MM units per day) of tablets, film, implants, transdermal patches with novel drug formulations, galenic and novel geometric structures

  • Cold-pressure process, enables wide range of API`s

  • Printing speed is significantly faster than for other 3D printing processes

Clinical Improvements

•Tailoring of pharmacokinetics
•Improved bioavailability
•Optimization of side effects
•Improves patient compliance